» Articles » PMID: 8921969

Characterization of H4: a Mouse T Lymphocyte Activation Molecule Functionally Associated with the CD3/T Cell Receptor

Overview
Journal Eur J Immunol
Date 1996 Nov 1
PMID 8921969
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

The monoclonal antibody C398.4A was produced by immunizing Armenian hamsters with the mouse T cell clone D10.G4.1. It recognizes a molecule selectively expressed by activated mouse T cells and was named H4. H4 is expressed on the T cell surface about 24 h after activation and peaks at day 7. By contrast, it is not expressed by resting or activated B cells, macrophages, or fibroblasts. It is also expressed by CD4 or CD8 single-positive mature thymocytes. Immunoprecipitation showed that H4 is a disulfide-linked dimer, precipitating as a broad band at about 50-65 kDa under nonreducing conditions and at 25 and 29 kDa under reducing conditions. Deglycosylation of the reduced H4 by N-glycanase gave rise to a single band of about 21 kDa, suggesting that the two chains may be differentially glycosylated forms of the same protein. The H4 expression pattern and biochemical features, together with cross-blocking, co-capping, co-modulation, and immunoprecipitation preclearing experiments showed that H4 is different from other known co-stimulatory molecules such as CD69, CD2, Ly-6, CD25, OX-40, Mac-1 and LFA-1. By in vitro kinase assay, H4 was found to co-precipitate a tyrosine kinase activity that phosphorylated substrates of about 29 and 25 kDa. Co-modulation and co-capping experiments showed that H4 is physically associated with the CD3/T cell receptor. These data suggest that H4 may function as a T cell-specific co-stimulatory molecule and play a role in the T cell response when the activation stimulus is limited either because the antigen is only available in low concentration or has a low agonistic activity.

Citing Articles

Transcriptional profile and immune infiltration in colorectal cancer reveal the significance of inducible T-cell costimulator as a crucial immune checkpoint molecule.

Chu J, Wu Y, Qu Z, Zhuang J, Liu J, Han S Cancer Med. 2024; 13(6):e7097.

PMID: 38506253 PMC: 10952025. DOI: 10.1002/cam4.7097.


Molecular and clinical characterization of ICOS expression in breast cancer through large-scale transcriptome data.

Wang P, Zhang Q, Zhang H, Shao J, Zhang H, Wang Z PLoS One. 2023; 18(12):e0293469.

PMID: 38127899 PMC: 10734928. DOI: 10.1371/journal.pone.0293469.


First-in-class small molecule inhibitors of ICOS/ICOSL interaction as a novel class of immunomodulators.

Abdel-Rahman S, Swiderek K, Gabr M RSC Med Chem. 2023; 14(9):1767-1777.

PMID: 37731692 PMC: 10507805. DOI: 10.1039/d3md00150d.


Parenteral Nanoemulsions Loaded with Combined Immuno- and Chemo-Therapy for Melanoma Treatment.

Monge C, Stoppa I, Ferraris C, Bozza A, Battaglia L, Cangemi L Nanomaterials (Basel). 2022; 12(23).

PMID: 36500861 PMC: 9740980. DOI: 10.3390/nano12234233.


Specific transcriptional programs differentiate ICOS from CD28 costimulatory signaling in human Naïve CD4 T cells.

Gigliotti C, Boggio E, Favero F, Incarnato D, Santoro C, Oliviero S Front Immunol. 2022; 13:915963.

PMID: 36131938 PMC: 9484324. DOI: 10.3389/fimmu.2022.915963.